Fairfax, VA (PRWEB) December 06, 2013
In their latest Special Report, “The Demand and Supply for Contract Manufacturing of Injectable Drugs Through 2019,” PharmSource experts provide a quantitative analysis on the latest trends and plans for outsourcing commercially approved injectable products.
Founded on the industry’s most comprehensive database of the dose CMO industry - PharmSource’s Strategic Advantage Database of Contract Service Providers - the analytical model and assumptions are fully explained so readers can understand how the analysis and conclusions were established. PharmSource is considered to be the most definitive, trustworthy source of strategic insight on this topic in the bio/pharmaceutical realm.
Projections are presented for key processing capabilities, including aseptic fill, lyophilized vials and prefilled devices such as syringes, cartridges and proprietary devices. The study analyzes the current capacity and planned additions to capacity of contract manufacturers, as well as the plans by major sponsors to increase in-house capacity.
This 80-page report gives important, expert insight that is not available in any other source. Over 25 tables and more than 20 charts and graphs throughout the report illustrate major points and trends. This report should be required reading for:
Copyright©2012 Vocus, Inc.
All rights reserved